FDA Approves Alhemo for Patients with Hemophilia
Routine prophylaxis to prevent or reduce bleedingFor Patients with Hemophilia A or B with Inhibitors
The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:
- Hemophilia A with factor VIII inhibitors, or
- Hemophilia B with factor IX inhibitors.
What It Is
- Alhemo is a subcutaneous (under the skin) injection, taken daily.
- It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.
Effectiveness
- In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
- Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.
Safety Info
- Most common side effects: Injection site reactions and hives.
- May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
- Not recommended for patients with serious allergies to the drug or its ingredients.
Special FDA Designations
- Priority Review
- Orphan Drug status (for rare conditions)
Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Announces Recall of GE Nuclear Medicine Systems
1200-pound Devices Could Fall on Patients On February 15, the FDA issued a statement announcing a recall of certain nuclear medicine systems manufactured by GE Healthcare. The recall involves the 600/800 Series nuclear medicine systems, which are used to diagnose and...
Regulatory Documentation for National and Global Market Access
With a solid base of technical documentation, our regulatory specialists will prepare a regulatory submission that is organized, well written, complete, and meets the regulatory requirements of the agency that will evaluate the product.
FDA Information – Conveniently Organized and Accessible
Quickly find the FDA information you need Conveniently organized FDA information. The U.S. Food and Drug Administration (FDA) provides a wealth of information for consumers and industry stakeholders. The problem is, it can be difficult to navigate to the information...